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Limited data exist regarding health care utilization (HCU) in patients receiving allogeneic hematopoietic cell
transplantation (alloHCT) for sickle cell disease. Financial data from 2002 to 2011 were analyzed for 26
alloHCT patients and 48 control subjects (referred but without alloHCT). HCU of alloHCT was determined over
3 time periods: pre-alloHCT, during alloHCT (day 0 to day þ365), and post-alloHCT. The median total cost per
patient during the alloHCT year was $413,000 inpatient and $18,000 outpatient. Post-alloHCT HCU decreased
when compared with pre-alloHCT and control subjects. The median cost of post-alloHCT outpatient visits per
patient was signiﬁcantly less when compared with pre-alloHCT (P ¼ .044). The median cost of post-alloHCT
inpatient visits per patient approached signiﬁcance when compared with those pre-alloHCT (P ¼ .079).
Sixteen post-alloHCT patients, 19 control subjects, and 14 unaffected siblings were surveyed using Pediatric
Quality of Life Inventory and EuroQOL questionnaires; however, the questionnaire scores across all 3 patient
groups were not statistically signiﬁcant (P ¼ .2638). When adjusted for health-related quality of life, the
analysis suggested alloHCT has a positive impact on health-related quality of life over control subjects. These
pilot data support our hypothesis that alloHCT in childrenwith sickle cell disease reduces HCU compared with
control subjects without alloHCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients with sickle cell disease (SCD) are plagued with
substantial morbidity, decreased life expectancy, and high
health care utilization (HCU). The treatment and manage-
ment of SCD is a substantial public health need. Currently,
allogeneic hematopoietic cell transplantation (alloHCT) is
the only curative option for patients with SCD and has seen
dramatic improvements in outcomes over the past 2
decades. As a result, alloHCT has become more available and
more readily recommended for evenyounger patients and/or
those with less severe disease. Therefore, the impact of this
shift in management must be analyzed in a way that
addresses outcomes, HCU, and health-related quality of life
(HRQOL). This analysis is integral for patient decision-
making and has substantial public policy implications.x.doi.org/10.1016/j.bbmt.2015.03.007.
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ty for Blood and Marrow Transplantation.SCD affects approximately 100,000 people in the United
States, and each year 2000 new diagnoses are detected via
newborn screening [1]. Over their lifetime, childrenwith SCD
suffer from disease-related complications that have an
adverse impact on quality of life and can lead to premature
death. These complications directly translate into substantial
HCU among this population.
Many studies have examined the clinical outcomes
and health care costs of SCD. In a study by Mvundura et al.
[2], US children with SCD represented > 1500 visits to the
emergency room and >1200 hospitalizations per year. In a
subsequent 2010 study, the total pediatric SCD-attributable
expenditures in the United States were estimated to be
about $335 million per year [3]. The US population of in-
dividuals with SCD reﬂects substantial HCU of up to $1.6
billion per year [4]. In the posthydroxyurea era, life expec-
tancy for sickle cell patients has increased from 30 years to
greater than 40 years, but this remains only about half that of
individuals without SCD in the United States [5]. With the
increase in life expectancy, the total annual hospitalization
S.D. Arnold et al. / Biol Blood Marrow Transplant 21 (2015) 1258e1265 1259cost has been documented at over $15 million for adults and
$2 million for children treated in the state of Maryland [6].
This difference in annual costs is attributed to the persistence
of SCD-related complications and irreversible end-organ
damage in adults even after the implementation of hy-
droxyurea therapy. These ﬁgures not only represent the
ﬁnancial impact on our health care system but also the
continued medical needs not being met by our current
treatment strategies.
Ultimately, these data must be adequately compared with
health outcomes and the cost of receiving alloHCT for SCD. A
number of studies have investigated curative approaches,
including alloHCT [7,8]. The success rate has risen to a 5-year
disease-free survival of 85% and an overall survival of 97%
with associated lower rates of post-alloHCT morbidity [9].
These outcomes improve further when limited to matched
sibling donor (MSD) alloHCT, thus making alloHCT a far more
viable option [10].
However, alloHCT carries a signiﬁcant ﬁnancial cost in the
ﬁrst year but then subsequently decreases rapidly over time.
The reported cost of alloHCT for adults with malignant or
nonmalignant conditions in the ﬁrst year ranges from
$96,000 to $204,000 [11]. This cost can vary based on con-
ditioning regimen, allograft type, and donor source. How-
ever, limited data exist on the cost associated with receiving
alloHCT for children with SCD.
Data on the impact of alloHCTonHRQOL are also limited. It
has been shown among pediatric alloHCT recipients that
HRQOL is worst immediately post-alloHCT but improves
substantially over time [12]. Kelly et al. [13] investigated this
among pediatric alloHCT recipients for hemoglobinopathies
and found a similar reduction in HRQOL immediately post-
alloHCT with return to baseline at 3 months post-alloHCT.
To date, no studies evaluate HRQOL in an isolated popula-
tion of children with SCD beyond 1 year post alloHCT and
correlate this with health care costs. In this pilot study, we
hypothesize that alloHCT will reduce HCU and cost when
compared with SCD control subjects while improving HRQOL.
METHODS
Patients and Eligibility
Patients aged 21 years or less were from the New York Presbyterian
Morgan Stanley Children’s Hospital of Columbia University Medical Center
with homozygous hemoglobin S disease, sickle hemoglobin C disease, sickle
bþ-thalassemia, or sickle b0-thalassemia. Control subjects were children
with SCD with documented HLA typing and/or alloHCT consultation during
the study period. Cases included eligible recipients of alloHCT within the
study period.
Patients received either a myeloablative conditioning regimen, which
consisted of busulfan (16 mg/kg), cyclophosphamide (120 to 200 mg/
kg)  rabbit antithymocyte globulin (8 mg/kg) or busulfan (12.8 to 16 mg/
kg), ﬂudarabine (180 mg/m2), and alemtuzumab (54 mg/m2), or a reduced-
intensity conditioning regimen, which consisted of melphalan (140 mg/m2),
ﬂudarabine (180 mg/m2), and alemtuzumab (54 mg/m2). When used,
alemtuzumabwas administered proximally. Acute graft-versus-host disease
(GVHD) prophylaxis consisted of tacrolimus  mycophenolate mofetil. In
addition, hospital standard operating practice was used for seizure pro-
phylaxis as well as infection prevention and prophylaxis as published pre-
viously [10].
Interrogating the Database
A retrospective review of the internal ﬁnancial data collected was per-
formed. This database contained cost and HCU information for each patient
encounter within the hospital, emergency department, or ambulatory
setting and served as the pilot cohort of data. Of note, the database did not
include any data on physician fees or cost. To date, our database includes
over 200 patients with SCD, and an additional 26 patients received alloHCT
for SCD from 2002 to 2012.
Study patients were identiﬁed using unique diagnostic codes. The
database was ﬁrst searched to identify disease-speciﬁc alloHCT patientsusing ICD-9 code 282.6 (International Classiﬁcation of Diseases, Ninth Revi-
sion) and alloHCT codes and/or descriptions. The generated patient list was
then compared with internal bone marrow transplant database records to
ensure data capture and accuracy. Once validated, a complete database
search was performed to obtain HCU information using patient medical
record numbers from the internal bone marrow transplant database for
alloHCT patients and alloHCT referrals.
Costs were recorded in terms of direct, indirect, and total costs from the
perspective of the health care institution or hospital; total costs were used as
the cost variable for analysis. Data on charges were also provided; however,
cost data only were analyzed as charges vary. These cost data included pa-
tient care setting (outpatient, inpatient, etc.) as well as inpatient length of
stay (LOS), number of inpatient visits, and number of outpatient visits.
Determining Costs and Utilization
The above ﬁnancial data were analyzed across the 2 groups: the alloHCT
case group and the control group. The HCU for the alloHCT group was
determined over 3 time periods: pre-alloHCT (before the start of condi-
tioning), during the alloHCT year (start of the conditioning regimen to
day þ365), and post-alloHCT (beyond day þ365). Control patients were
analyzed over the duration of care at the institution within the study period
of 2002 to 2012.
To provide statistically relevant analysis, patients with less than
6 months of ﬁnancial data within the pre- or post-alloHCT periods of the
study were excluded. This included 5 patients who transferred care to
another institution with their primary transplant attending and therefore
lacked complete post-alloHCT data. Another 3 patients were referred to our
institution for alloHCT and therefore lacked sufﬁcient pre-alloHCT data. An
additional 4 patients died during the alloHCT year and therefore lacked
post-alloHCT data. Because of the small sample size, HCU data could not be
extrapolated for inclusion in the analysis, making these patients unassess-
able in the comparative analysis. This resulted in an assessable sample size
of 14 patients for HCU. However, all alloHCT patients had assessable data
during the alloHCT year and were therefore included in the analysis for this
period. The data from this time period of the study were not used for case-
control comparative analysis.
Because the amount of data available for alloHCT patients varied based
on date of transplant within the study period, all HCU variables were
determined in terms of HCU per patient per month. This established a
standard or constant data point for comparison between patients and pa-
tient groups.
HRQOL
Surviving alloHCT recipients and control subjects were surveyed after
HCU data collection using age-appropriate Pediatric Quality of Life Inventory
(PedsQL) and EuroQOL (EQ-5D) questionnaires. Post-alloHCT siblings
without SCD were also surveyed as the unaffected control subjects. PedsQL
queries HRQOL across 4 scalesdphysical, emotional, social, and school
functioningdbased on recall over the past month [14]. A total scaled score
was then determined using the PedsQL scoring algorithm.
EQ-5D provides a 2-part assessment of 5 dimensions of functio-
ningdmobility, self-care, usual activities, pain/discomfort, and anxiety/
depressiondas experienced at the time of the survey and an overall self-
report of health status in the visual analogue scale (VAS) [15]. Mean
HRQOL scores (maximum score of 100 for PedsQL and EQ-5D VAS) were
calculated for each of the 3 groups. Utility scores were determined based on
EQ-5D responses using established valuation methods and US value sets
[16]. Scores were compared usingWilcoxon rank sum ordering to determine
signiﬁcance.
The quality-adjusted life year (QALY) for each patient in the alloHCT year
was then determined using the sum of the interval average utilities and time
at days þ45, þ90, þ180, and þ365 based on utility norms from previously
published data [13]. To compare alloHCT patients to control subjects, the
incremental cost-effectiveness ratio (ICER), the ratio of the change in costs to
incremental beneﬁts of alloHCT, was calculated as the difference in annual
costs for the comparison groups divided by the change in QALY as deter-
mined using the area under the curve [17].
Statistical Considerations
Most of the HCU analysis was descriptive. The cumulative HCU per pa-
tient depended on the follow-up time and can be inﬂuenced by terminal
event death. Those patients without corresponding inpatient HCU variables
to outpatient were assigned 0 value for calculations. The mean and standard
deviation (SD) were calculated; median and range were also reported.
The comparison between pre- and post-alloHCT groups was carried out
using the generalized linear models with identity link and normal error for
the comparison of the cost of inpatients and cost of outpatients and by the
generalized linear models with Poisson distribution and log link for the
Table 1
Demographic and Disease Characteristics of alloHCT Recipients and Control
Subjects
Variables AlloHCT
(n ¼ 26)
Control
Subjects
(n ¼ 48)
P
Analysis compared with all alloHCT recipients within the study period
Mean age, yr 9.10  6.25 4.23  3.74 .001
Gender .010
Female 5 (19%) 24 (50%)
Male 21 (81%) 24 (50%)
Prior treatment 16 (62%) 26 (54%) .541
Hydroxyurea 9 (34.6%) 22 (46%)
Chronic transfusions 10 (38%) 4 (8%)
Sickle cellerelated complications
VOC 20 (77%) 41 (85%) .361
ACS 16 (61%) 35 (73%) .431
CVA 3 (11%) 4 (8%) .691
Variables Pre/Post-
AlloHCT
(n ¼ 14)
Control
Subjects
(n ¼ 48)
P
Analysis compared with assessable alloHCT recipients used in HCU
comparison
Mean age, yr 4.45  4.45 4.23  3.74 .855
Gender .072
Female 3 (21.4%) 24 (50%)
Male 11 (78.6%) 24 (50%)
Prior treatment 6 (42.9%) 26 (54%) .456
Hydroxyurea 3 (21.4%) 22 (46%)
Chronic transfusions 5 (35.7%) 4 (8%)
Sickle cellerelated complications
VOC 10 (71%) 41 (85%) .249
ACS 6 (43%) 35 (73%) .054
CVA 1 (7%) 4 (8%) 1.0
VOC indicates vaso-occlussive crisis; ACS, acute chest syndrome; CVA, ce-
rebrovascular accident.
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S.D. Arnold et al. / Biol Blood Marrow Transplant 21 (2015) 1258e12651260comparison of inpatient visits, outpatient visits, and LOS. HCU during the
alloHCT year was compared across various clinical variables by univariate
logistic regression on upper quartiles of HCU variables in the alloHCT year
only. Multivariate analysis was not performed because of the small sample
size and lack of sufﬁcient power for this type of analysis. All outcomes with a
P < .05 were considered statistically signiﬁcant. All analysis was carried out
using SAS software (version 9.3; SAS institute, Cary, NC).
RESULTS
Demographics
The alloHCT cohort included 26 patients (mean age at
alloHCT, 9.10 years [SD, 6.25]). Twenty-one patients were
male and 5 patients were female (Table 1). Most patients had
prior vaso-occlusive crisis followed by acute chest syndrome
and a small percentage of cerebrovascular accidents. In
addition, 62% received chronic treatment with either hy-
droxyurea or chronic transfusions before alloHCT.
Most alloHCTs used either cord blood or bone marrow,
with 48% each, and the remainder peripheral blood stem
cells. Almost two-thirds of alloHCT recipients had related
donor, or MSD, of all donor sources, with the remaining
unrelated donor alloHCT consisting of all unrelated cord
blood transplant (UCBT) recipients. Most were transplanted
with a myeloablative conditioning regimen. Nineteen
patients were conditioned with busulfan, ﬂudarabine,
and alemtuzumab; 6 with busulfan, cyclophosphamide, 
r-rabbit antithymocyte globulin only; and 1 received
melphalan, ﬂudarabine, and alemtuzumab. Cytomegalovirus
(CMV) reactivation occurred in 27% of patients. Acute GVHD
occurred in 27% of patients in the alloHCT year. Morbidity,
deﬁned by development of chronic GVHD, only occurred in
4% of patients (n ¼ 1). This patient since has had complete
resolution of GVHD. The 3-year event-free survival rate for
Figure 1. Overall post-alloHCT HCU per patient per month compared with pre-alloHCT and control subjects. The horizontal lines that form the top and bottom of
each box are the 75th and 25th percentiles, respectively. The horizontal line that intersects the box is the median. The whiskers represent the minimum and
maximum ranges. The solid squares represent the mean values. (See Supplemental Table 1 for exact HCU ﬁgures.)
S.D. Arnold et al. / Biol Blood Marrow Transplant 21 (2015) 1258e1265 1261patients receiving MSD alloHCT was 100% and for UCBT re-
cipients 55.6%. The latter included 1 graft failure and 4 deaths
from graft failure and/or viral infection. As a result, event-
free survival was impacted by 15% primary graft failure and
overall transplant-related mortality of 15%.
The control cohort included 48 patients (mean age,
4.23 years [SD, 3.74]; P ¼ .001 when compared with pre-
alloHCT); this group had an equal gender distribution (50%
male, 50% female; P ¼ .010). Most patients had prior vaso-
occlusive crisis (85%) followed by acute chest syndrome
(73%) and cerebrovascular accidents (8%), which did not have
a signiﬁcant difference from the alloHCTgroup (P¼ .361, .431,
and .691, respectively) (Table 1). Of these, 54% received
chronic SCD treatment with either hydroxyurea or chronic
transfusions (P ¼ .541). All patients were followed at our
center and received routine comprehensive care and sup-
portive care according to established, standard guidelines.
This group had no documented mortality during the study
period.
Utilization
Pre-alloHCT
Fourteen patients were included in the pre-alloHCT
analysis (mean age, 4.45 years [SD, 4.45]) (Table 1) over a
median of 30 patient care months (range, 7 to 103). A total of
76 inpatient admissions (range, 1 to 16 per patient) with a
median LOS of 17 days per patient (range, 4 to 48) were
recorded. This represented amedian total cost of $42,050 per
patient (range, $4551 to $100,619). All patients hadoutpatient visits totaling to 752 visits (range, 5 to 139 per
patient) with a median total cost of $21,176 per patient
(range, $4745 to $68,605).
AlloHCT year
For the 26 transplanted patients, themedian total cost per
patient during the alloHCT year was $413,070 (range,
$155,265 to $1,554,690) inpatient and $17,791 (range, $5175
to $88,526) outpatient. This included 94 inpatient admis-
sions (range, 1 to 8 per patient) and a median LOS of 67 days
per patient (range, 29 to 226). Outpatient data included only
23 patients, because 3 patients died during their initial
alloHCT admission. Of these, a total of 1060 visits were
recorded (range, 11 to 91 per patient).
HCU of the upper quartiles during this period was
compared across various clinical variables using logistic
regression (Table 2). A statistically signiﬁcant increase in
inpatient cost and LOS was associated with alloHCT re-
cipients who had a UCBT (odds ratio [OR], 32; P ¼ .006),
developed acute GVHD (OR, 7; P ¼ .047), and/or had CMV
reactivation (OR, 7; P ¼ .047) compared with those who did
not. In addition, patients with acute GVHD had signiﬁcantly
higher numbers of inpatient admissions (P ¼ .047) and
outpatient visits (P ¼ .038).
Donor source for all patients was analyzed separately;
average LOS did not remain signiﬁcant between UCBT and
MSD recipients (127 days versus 70 days per patient;
respectively, P ¼ .661). However, average cost remained
signiﬁcantly higher for UCBT recipients when compared with
Figure 2. Overall post-alloHCT costs (in US$) per patient per month compared with pre-alloHCT and control subjects. The horizontal lines that form the top and
bottom of each box are the 75th and 25th percentiles, respectively. The horizontal line that intersects the box is the median. The whiskers represent the minimum
and maximum ranges. The solid squares represent the mean values. (See Supplemental Table 1 for exact cost ﬁgures.)
S.D. Arnold et al. / Biol Blood Marrow Transplant 21 (2015) 1258e12651262MSD recipients ($705,242 versus $336,607 per patient,
respectively; P ¼ .027).
Post-alloHCT
HCU in this period spanned a median of 38 patient care
months (range, 9 to 82). Six of 14 assessable patients had 10
admissions (range, 1 to 3 per patient) with a median LOS of
2 days per patient (range,1 to 32). This represented a median
total cost of $5170 per patient (range, $744 to $141,587). All
patients had outpatient visits totaling to 381 visits (range, 8
to 61 per patient) with a median total cost of $12,738 per
patient (range, $6484 to $30,058).
Control subjects
All patients in the control cohort had assessable outpa-
tient and inpatient data, with 544 inpatient admissions
during the study period (median, 8 days; range, 1 to 62 per
patient) and a median LOS of 21 days per patient (range, 1 to
171). This represented a median total cost of $55,414 per
patient (range, $3219 to $425,396). Outpatient care consisted
of 3870 visits (range, 5 to 281 per patient) at a median total
cost of $18,795 per patient (range, $1559 to $148,803). These
patients had amedian total health care cost of $8245 per year
(range, $530 to $63,800).
Caseecontrol comparison
As above, assessable alloHCT patients used for compari-
son were not signiﬁcantly different from control subjects interms of demographic, disease, or treatment-related vari-
ables (Table 1). Patients in the post-alloHCT period had
signiﬁcantly fewer inpatient visits per month and lower LOS
when compared with pre-alloHCT and with the control
group (Figure 1). The associated median post-alloHCT costs
per month were not signiﬁcant ($0 [range, $0 to $2102]
versus $730.00 per month [range, $0 to $14,026], P ¼ .079)
(Figure 2).
In the outpatient setting, the number of post-alloHCT
visits was again signiﬁcantly lower than when compared
with pre-alloHCT and with control subjects (Figure 1). This
was associated with a signiﬁcant reduction in median post-
alloHCT cost per patient per month when compared with
pre-alloHCT ($295.00 [range, $153 to $1435] versus $781.80
per month [range, $230 to $2709], P ¼ .044) (Figure 2).
HRQOL
Sixteen post-alloHCT patients (mean age,15 years [SD, 5])
and 19 control subjects (mean age, 12 years [SD, 5]) were
surveyed. Post-alloHCT patients completed the survey, on
average, 6 years post-alloHCT. SCD therapy was documented
in terms of treatment pre-alloHCT in the “post-alloHCT”
cohort and at any time period greater than 6 months for the
control group. SCD therapy included hydroxyurea (post-
alloHCT, n ¼ 8; control subjects, n ¼ 10) and chronic trans-
fusions (post-alloHCT, n ¼ 7; control subjects, n ¼ 2). Most
patients remained in school (post-alloHCT, n ¼ 12; control
subjects, n ¼ 19), whereas the remaining 4 post-alloHCT
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Figure 3. Overall post-alloHCT HRQOL scores for A) PedsQL, B) EQ5D-Visual
Analogue Scale, C) EQ5D-Utility compared with control subjects and siblings
(P ¼ .2638).
S.D. Arnold et al. / Biol Blood Marrow Transplant 21 (2015) 1258e1265 1263patients worked full time. Of the post-alloHCT patients, only
1 had a history of chronic GVHD.
The mean scaled scores were 83 for post-alloHCT patients
and 81 for control subjects. Similarly, the mean EQ-5D VASscores were 92 and 87, respectively. The mean EQ-5D utility
scores were .87 and .91, respectively (Figure 3). The lowest
mean PedsQL scores for the post-alloHCT group were school
and social functioning (76 and 82, respectively), whereas
control subjects were lowest in school and physical func-
tioning (77 and 78, respectively). The mean EQ-5D scores
when post-alloHCT was compared with control subjects
were highest for self-care (1 and 1, respectively) and lowest
for pain (.949 and .954, respectively).
In addition, the post-alloHCT group was compared with a
cohort of unaffected sibling donors (mean age, 14 years [SD,
6]). Sibling mean scores were 88 for PedsQL, 96 for EQ-5D
VAS, and .89 for EQ-5D utility. The difference in overall or
total scores across all 3 groups was not statistically signiﬁ-
cant (P ¼ .2638).
The established norms of utility for days þ45, þ90, þ180,
and þ365 were .71, .75, .79, and .84, respectively, from a
baseline utility of .75 (personal communications, Susan K.
Parsons, Tufts University, 2014) [13]. The alloHCT year has an
estimated ICER of about $467,000 per QALY (Table 3). Anal-
ysis of the change in HRQOL for alloHCT compared with in-
dividuals with SCD performed using the area under the curve
showed a QALYof .78 and a loss of .13 occurs in the transplant
year when compared with study control subjects [17].
However, when the alloHCT HRQOL was compared with the
published utility of adults living with SCD, a QALY gain of .08
occurs [19]. Assuming a life expectancy of 50 years for adults
with SCD and lifetime post-alloHCT costs at US per capita
expenditures, this translates into an average gain of 10 years
of life for post-alloHCT recipients over their lifetime, with an
estimated ICER of about $160,000 per QALY (Table 3).
DISCUSSION
To date, this is the ﬁrst published study analyzing HCU
and cost of alloHCT for children with SCD. We demonstrated
that despite substantial cost during the alloHCT year, HCU
decreases signiﬁcantly over time post-alloHCT when
compared with that pre-alloHCT and with control subjects.
More importantly, this change is associated with signiﬁcant
HRQOL improvements.
We describe a median transplant cost of approximately
$413,000 per patient during the transplant year. This is
substantially higher than published reports of $96,000 to
204,000 for alloHCT in adult recipients for hematologic dis-
orders [11]. However, pediatric alloHCT cost data have been
reported at $377,000 to $457,000 during the ﬁrst year post-
alloHCT for pediatric acute leukemia [20], suggesting that
factors unique to pediatric populations confer increased
costs compared with adults.
Univariate analysis of our cohort identiﬁed factors that
may uniquely affect HCU in pediatric alloHCT. First, our
experience with UCBT and the high mortality are likely
contributors to the high inpatient cost. However, this effect
could not be studied further because the UCBT arm of the
study was closed due to poor clinical outcomes [21].
Second, our data on GVHD are consistent with the ﬁnd-
ings of Svahn et al. [22], who showed a statistically signiﬁ-
cant increase in cost with high-grade acute GVHD and
unrelated donor transplant. Patients with acute GVHD in our
cohort had signiﬁcantly higher outpatient visits and inpa-
tient HCU including cost. Based on prior publications, the
increased cost is presumed due to higher readmission rates
for morbidities such as GVHD [23]. This creates a potential
source of further investigation in preventing and managing
GVHD in our patient population.
Table 3
QALY Across 3 Patient Groups
Day þ45 Day þ90 Day þ180 Day þ365 Total QALY Predicted Lifetime
AlloHCT year utility* .71 .75 .79 .84 .78
AlloHCT year median cost, $ 204,404 87,184 38,542 11,679 341,809
ICER, D$/QALY 287,893 116,246 48,788 13,904 466,830 983,497y
Control utility .91
Control median cost, $ 8245
ICER, D$/QALY 9060
Adult SCD cost, $ 16,000z .7x
ICER, D$/QALY 22,857 1,142,857
Italics reﬂect directly referenced data and/or that derived from referenced data.
* Personal communication, Susan K. Parsons, Tufts University, 2014.
y From [18].
z From [4].
x From [19], adult SCD utility ¼ 0.7.
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CMV reactivation. CMV reactivation was associated with
increased HCU and higher mortality especially among our
UCBT arm. Other published studies have shown similar to
higher rates of CMV reactivation and/or viremia among pe-
diatric UCBT recipients for SCD [24]. This is presumably a
consequence of our alemtuzumab-based protocols because
this risk has previously been identiﬁed in the literature
[25,26]. As a result, investigation of modiﬁed conditioning
regimens and prophylactic regimens based on donor source
and CMV status is necessary.
At the same time, our analysis supported the lower HCU
associated with MSD alloHCT. Previous studies have deter-
mined that related donor transplant is less costly than
matched unrelated donor or UCBT in the ﬁrst 100 days after
alloHCT [27]. Our study supported this ﬁnding during this
period and even throughout the remainder of the alloHCT
year. This, in conjunction with a 3-year evert-free survival
rate of 100%, further suggests that MSD alloHCT is a viable
upfront treatment option for children with SCD and an
available MSD.
In addition, the morbidity impact on HCUwas explored in
the context of HRQOL. Our alloHCT patient cohort has simi-
larly been studied and recapitulates the ﬁndings of previ-
ously published work showing a statistically signiﬁcant
improvement in HRQOL over the ﬁrst year post-alloHCT
when compared with pre-alloHCT [28]. Although the
HRQOL analysis in this study was performed at 1 point in
time, the ﬁndings of our population are representative of
published literature in that post-alloHCT patients have
HRQOL scores similar to unaffected siblings, indicating
HRQOL normalizes post-alloHCT [13,28].
In addition, the control sample of SCD patients also had
HRQOL scores similar to unaffected siblings. This may reﬂect
the high hydroxyurea usage at our institution (53% among
those who completed HRQOL surveys). The difference in
maintenance SCD therapy suggests a difference that when
compared with alloHCT recipients was not statistically sig-
niﬁcant. At the same time, a signiﬁcant difference in the
quality-adjusted cost represents a potential gain in quality
life at $60,000 for QALY gained. These factors in tandem
suggest that reduced hospitalization post-alloHCT has a
signiﬁcant impact not only on HCU but also on HRQOL.
Our data suggest a cost-to-beneﬁt advantage of alloHCT
over standard therapy. This also provides the ﬁrst analysis of
HRQOL as an outcome and the economic impact of alloHCT
for pediatric SCD patients. These ﬁndings afﬁrm that alloHCTis cost-effective and, more importantly, a beneﬁcial man-
agement option for patients.
Limitations of Analysis
This study incorporates single-institution retrospective
data that do not allow for complete, prospective analysis of
outcomes, quality, and HCU. As such, it did not allow for
randomization, and a control group had to be identiﬁed
based on predictions about the patient population. The use of
patients who were HLA typed and/or received alloHCT
consultation assumes similarity, yet this introduces bias into
the comparison. Speciﬁcally, the difference in maintenance
SCD therapy suggests a difference in the control subjects
when compared with alloHCT recipients that favors patients
with more severe SCD including chronic transfusions. How-
ever, overall differences in SCD therapy and complications
were not statistically signiﬁcant.
Similarly, this analysis also does not account for the key
variables like the impact of duration of survival or LOS.
Speciﬁcally, this analysis does not allow for post-alloHCT
comparison for patients who died during the alloHCT year.
Our ability to perform long-term analysis is inherently
limited among this group. However, these patients were
included in the univariate analysis and likely reﬂect the
increased cost among the unrelated, graft failure, and CMV
reactivation groups. Finally, we point out that this study is
more of pilot study and lacks a sensitivity analysis on key
variables because of a small sample size.
In addition, our analysis of alloHCT does not include
assessment of donor or procurement related costs. In a study
of children receiving alloHCT from 2004 to 2006, these costs
were estimated at around $9000 for matched unrelated do-
nors and $60,000 for UCBT [27]. Therefore, these costs could
have substantial implications related to the cost and
outcome of UCBT. In addition, it does not clearly delineate
pre-alloHCT costs from those associated with evaluation and
preparation for alloHCT. In a study by van Agthoven et al.
[29], most transplant-associated costs were incurred during
the initial alloHCT admission, suggesting that these costs
may be minimal in the pre-alloHCT period.
Finally, our database was not comprehensive in inclusion
of fees, including physician or provider fees. However, this
was deemed negligible at least in the outpatient setting.
Ultimately, because no baseline data on this populationwere
available for reporting, the institutional database was
selected based on its comprehensiveness on location of ser-
vice including inpatient, outpatient, and emergency HCU, the
S.D. Arnold et al. / Biol Blood Marrow Transplant 21 (2015) 1258e1265 1265latter of which are not available in publicly available ﬁnancial
databases.
Future Studies
This study will serve as the impetus for future research
including investigation of speciﬁc contributors to HCU such
as laboratory, transfusion, and medication costs. In addition,
cost-to-beneﬁt analysis will be performed that includes
HRQOL assessment over time of not only alloHCT recipients
but also of control subjects. Finally, although our sample was
reﬂective of national standards for morbidity and mortality
in this patient population, it is not a representative sample. A
largemulticenter study is required to validate these results. If
more representative, national ﬁndings are consistent,
alloHCT should be accepted as standard of care curative
therapy for SCD and therefore reimbursable by public and
private insurers.
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